Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study - PubMed
4 hours ago
- #triplet therapy
- #prostate cancer
- #metastatic hormone-sensitive
- The ARON-3 study compared doublet therapy (ADT + ARPI) vs triplet therapy (ADT + ARPI + docetaxel) in high-volume metastatic hormone-sensitive prostate cancer (mHSPC) patients with bone metastases.
- Primary endpoints included time to treatment failure (TTF), PSA response, and overall survival (OS).
- In patients with >10 bone metastases, triplet therapy showed significant improvement in adjusted TTF (HR 0.49, p=0.02), while OS improvement was numerical but not statistically significant (HR 0.48, p=0.1).
- Triplet therapy at 12 weeks was associated with changes in opioid use and ECOG performance status.
- Median OS for ADT + abiraterone acetate was 63.0 months, while it was not reached for other regimens like ADT + apalutamide, ADT + enzalutamide, and ADT + docetaxel + darolutamide.
- TTF and OS estimates varied by bone metastatic burden, but formal interaction testing showed no evidence of heterogeneity, requiring prospective validation.